Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 12/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427564 | 1.00 | GNPAT (0.48) | GNPATENPEPMMEECE1NOD1 | |
| SCHEMBL29384981 | 0.97 | ENPEP (0.44) | GNPATENPEPMMEECE1NOD1 | |
| SCHEMBL30799660 | 0.94 | GNPAT (0.44) | GNPATENPEPMMENOD1 | |
| SCHEMBL30798028 | 0.93 | GNPAT (0.53) | GNPATENPEPMMEECE1NOD1 | |
| SCHEMBL30798044 | 0.93 | GNPAT (0.53) | GNPATENPEPMMEECE1NOD1 | |
| SCHEMBL30337275 | 0.91 | GNPAT (0.50) | GNPATENPEPNOD1 | |
| SCHEMBL29630390 | 0.91 | MME (0.48) | GNPATMME | |
| SCHEMBL31181213 | 0.90 | GNPAT (0.47) | GNPATENPEPMMENOD1 | |
| SCHEMBL7825934 | 0.90 | MME (0.49) | GNPATENPEPMMEECE1NOD1 | |
| SCHEMBL29378709 | 0.90 | MME (0.49) | GNPATENPEPMMEECE1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629446-B2 | Vascular embolic system | 3-D MATRIX, LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20250311587-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12377196-B2 | Preventing biological tissue adhesion | 3-D MATRIX, LTD. (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250177614-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20230241294-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20220168462-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220111126-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629446-B2 | Vascular embolic system | TNNI3, MYLK, ADM2 | GNPAT 4629/4885ENPEP 757/4885MME 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.